Article citationsMore>>

I. Vergote, C. G. Tropé, F. Amant, G. B. Kristensen, T. Ehlen, N. Johnson, R. H. Verheijen, M. E. van der Burg, A. J. Lacave, P. B. Panici, G. G. Kenter, A. Casado, C. Mendiola, C. Coens, L. Verleye, G. C. Stuart, S. Pecorelli, N. S. Reed, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group and NCIC Clinical Trials Group, “Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer,” New England Journal of Medicine, Vol. 363, No. 10, 2010, pp. 943-953. doi:10.1056/NEJMoa0908806

has been cited by the following article:

• TITLE: Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome

  AUTHORS: Nadine Rudiger, Ernst-Ludwig Stein, Erika Schill, Gabriele Spitz, Carola Rabenstein, Martina Stauch, Matthias Rengsberger, Ingo B. Runnebaum, Ulrich Pachmann, Katharina Pachmann

  KEYWORDS: Circulating Epithelial Tumor Cells; Chemosensitivity Testing; Breast Cancer; Ovarian Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.2, April 22, 2013

  ABSTRACT: Background: Chemotherapy is a mainstay of tumor therapy, however, it is predominantly applied according to empirically developed recommendations derived from statistical relapse rates occurring years after the treatment in the adjuvant situation and from progression-free interval data in the metastatic situation, without any possibility of individually determining the efficacy in the adjuvant situation and with loss of time and quality of life in the metastatic situation if the drugs chosen are not effective. Here, we present a method to determine the efficiency of chemotherapeutic drugs using tumor cells circulating in blood as the part of the tumor actually available in the patient’s body for chemosensitivity testing. Methodology/Principal Findings: After only red blood cell lysis, omitting any enrichment (analogous to other blood cell enumeration methods, including rare CD34 cells), the white cells comprising the circulating epithelial tumor cells (CETC) are exposed to the drugs in question in different concentrations and for different periods of time. Staining with a fluorescence-labeled anti-epithelial antibody detects both vital and dying tumor cells, distinguishing vital from dying cells through membrane permeability and nuclear staining with propidium iodide. Increasing percentages of dying tumor cells are observed dependent on time and concentration. The sensitivity can vary during therapy and was correlated with decrease or increase in CETC and clinical outcome. Conclusions/Significance: Thus, we are able to show that chemosensitivity testing of circulating tumor cells provides real-time information about the sensitivity of the tumor present in the patient, even at different times during therapy, and correlates with treatment success.